COMMUNIQUÉS West-GlobeNewswire

ITM and Lumara Bio Announce Upcoming Dosimetry and Re-treatment Data Presentations on ¹⁷⁷Lu-edotreotide at ASTRO 2026
23/09/2026
Garching / Munich, September 23 , 2026 — ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, and Lumara Bio , a dedicated oncology therapeutics division of ITM, today announced that [...]
La rage chez les otaries à fourrure du Cap : ce que les nouvelles recherches sud-africaines pourraient signifier pour le Canada
23/09/2026
OTTAWA, Ontario, 23 sept. 2026 (GLOBE NEWSWIRE) -- L’Institut canadien de santé animale (ICSA) est fier de perpétuer sa tradition annuelle consistant à organiser un webinaire éducatif à l’occasion de la Journée mondiale [...]
Rabies in Cape Fur Seals: What New South African Research Could Mean for Canada
23/09/2026
OTTAWA, Ontario, Sept. 23, 2026 (GLOBE NEWSWIRE) -- The Canadian Animal Health Institute (CAHI) is proud to continue its annual tradition of hosting an educational webinar in recognition of World Rabies Day. This year’s [...]
Change in Roche’s Board of Directors
23/09/2026
Roche announced today that the Board of Directors of Roche Holding Ltd has approved to propose Dr. Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board of Directors at Roche’s Annual General [...]
Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)
23/09/2026
In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential Sefaxersen inhibits [...]
OSE Immunotherapeutics annonce la présentation des principaux résultats de l'étude de Phase 2 Combi-TED de Tedopi® dans le cancer du poumon non à petites cellules au Congrès 2026 de l’ESMO
23/09/2026
Nantes, France, 23 septembre 2026 – 7h30 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE) , une société de biotechnologie au stade clinique développant des thérapies first-in-class en immuno-oncologie [...]
OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting
23/09/2026
Nantes, France, September 23, 2026 – 7:30am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and [...]
The Hemp Doctor's Cannabis Consumer Behavior Survey: Average Buyer Is 45
23/09/2026
A 10,214-response survey from The Hemp Doctor finds its customers are older, more self-directed, and more cannabinoid-literate than most of the industry has assumed MOORESVILLE, N.C., Sept. 23, 2026 (GLOBE NEWSWIRE) -- [...]
Anaconda Biomed Secures $56 Million Financing from New and Existing Investors
23/09/2026
Proceeds used to complete ongoing ATHENA pivotal IDE study, continue product development, and secure global regulatory approvals for neurovascular portfolio BARCELONA, Spain and MARIN, Calif., Sept. 23, 2026 (GLOBE [...]
InnovAge Announces Pricing of Secondary Offering of Common Stock by Selling Stockholders
23/09/2026
DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible [...]
IN8bio to Present at Sidoti Small-Cap Virtual Conference
22/09/2026
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune [...]
Acquisition of Own Shares
22/09/2026
Mechelen, Belgium; September 22, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") [...]
InnovAge Announces Launch of Proposed Secondary Offering of Common Stock by Selling Stockholders
22/09/2026
DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible [...]
Biomea Fusion Announces Proposed Public Offering of Securities
22/09/2026
SAN CARLOS, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
22/09/2026
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 22 sept. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
Voting Rights and Shares Capital of the Company
22/09/2026
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Sept. 22, 2026 (GLOBE NEWSWIRE [...]
Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
22/09/2026
TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“ Helus ” or the “ Company ”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel [...]
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
22/09/2026
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced that its Board of Directors has authorized a cash dividend to [...]
Hyagen Medical Participates in PepMed 2026 to Discuss Regulatory Clarity in Stem Cell Therapy
22/09/2026
Hyagen Medical founder Chuck Meeker, Ph.D., Esq., joins regenerative medicine leaders in Washington to examine how classification, regulatory clarity and responsible communication could shape the future of the field in [...]

Pages